Iterum Therapeutics Plc (NASDAQ:ITRM) currently has a daily average trading volume of 382.87K but it saw 1014064 shares traded in last market. With a market cap of 40.66M USD, the company’s current market price of $1.05 came rising about 13.87 while comparing to the previous closing price of $0.92. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.02 and as low as $0.81.
Taking a look at 20-day trading activity of Iterum Therapeutics Plc (ITRM) gives us an average price of $1.1159, while its current price level is -65.23% below from 52-week high level whereas it is 29.95% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2343 while that of 200 days or SMA-200 reads an average of $1.3802. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.15% during that period while stretching the period over a month that decreases to 8.29%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 44.34 which implies that the stock is in neutral territory.
H.C. Wainwright upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 15, 2021 while assigning a price target of $2.50. RBC Capital Mkts issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $7 and $2.
Over the week, ITRM’s stock price is moving -2.78% down while it is -5.41% when we observe its performance for the past one month. Year-to-date it is -40.68% down and over the past year, the stock is showing a downside performance of -32.26%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Iterum Therapeutics Plc’s total number of outstanding shares is 38.73M with 1.15% of that held by the insiders while 8.57% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -91.79% and return on equity (ROE) at -555.68%. Stock’s beta reads 2.88. Its return on asset (ROA) is -69.93% on average.
